<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Nodify Lung Nodule Risk Assessment


nodifycdt-600

Nodify CDT™ testing helps identify patients with likely malignant lung nodules and supports clinical decision-making so physicians can more confidently identify patients who may benefit from timely intervention.

Learn more about:

NODIFY LUNG TESTING STRATEGY

NODIFY XL2 TEST

What does the Nodify CDT test measure and how does it work?

 

Who is eligible for Nodify CDT?

Nodify CDT is intended for patients with incidental lung nodules:

DOWNLOAD THE NODIFY CDT TEST RESULT REPORT

Clinically Validated Results

  • The Nodify CDT test measures autoantibodies to tumor-associated antigens to help physicians detect lung cancer across histologies and stages.1,2
  • In the clinical validation study3, Nodify CDT demonstrated a test performance of 98% specificity with a 78% positive predictive value (PPV) for the High Level test result.

READ THE CLINICAL VALIDATION PUBLICATION

Interested in ordering Nodify Lung testing?

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT and the Nodify XL2 proteomic tests.

DOWNLOAD OUR INFORMATIONAL BROCHURE
ORDER NODIFY LUNG TESTING
CONTACT OUR TEAM

Get in touch

Contact Us

Data library

Discover More
  1. Jett J, Healey G, Macdonald I, et al. “Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort.” Journal of Thoracic Oncology. 2017; 12(11): S2170.
  2. Chapman C, Healey G, Murray A, et al. “EarlyCDT—Lung test: improved clinical utility through additional autoantibody assays.” Tumor Biology. 2012; 33(5):1319–1326.
  3. Healey et al ”Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT-Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary Nodules” Journal of Cancer Therapy. 2017. 8, 506-517.